Rodman & Renshaw Initiates Coverage On Quince Therapeutics with Buy Rating, Announces Price Target of $70

Benzinga Newsdesk www.benzinga.com Positive 60.3%

Neg 0% Neu 0% Pos 60.3%

Rodman & Renshaw analyst Seema Sheoran initiates coverage on Quince Therapeutics (NASDAQ:QNCX) with a Buy rating and announces Price Target of $70.